Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: DRUG: ladiratuzumab vedotin|DRUG: Pembrolizumab
Sponsor: Seagen Inc.
Collaborators: Merck Sharp & Dohme LLC